Showing 4071-4080 of 9772 results for "".
- Long-acting Reversible Contraception Linked with Acne Young Adults: Analysishttps://practicaldermatology.com/news/relationship-between-long-acting-reversible-contraception-and-acne-in-a-cohort-of-adolescents-and-young-adults/2462264/The use of progestin-only long-acting reversible contraception (LARC) may have an increased risk of developing acne or experiencing worsening of acne symptoms, a new analysis indicates. "Few studies have focused primarily on the effects of hormonal LARC on the developmen
- Pediatric Atopic Dermatitis Associated with Learning, Memory Difficultieshttps://practicaldermatology.com/news/symptoms-of-cognitive-impairment-among-children-with-atopic-dermatitis/2462263/New research links pediatric atopic dermatitis (AD) with higher odds of memory and learning difficulties. "Previous studies suggest that atopic dermatitis (AD) is associated with cognitive impairment in children, but these studie
- Report: Unacceptably High Benzene Levels Detected in Numerous Acne Products Containing BPOhttps://practicaldermatology.com/news/report-unacceptably-high-benzene-levels-detected-in-numerous-acne-products-containing-bpo/2462262/An independent laboratory has reported that it has detected elevated levels of benzene in a number of widely used acne products, according to a press release. Valisure, an independent testing laboratory based in Connecticut, has filed a
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investi
- 595-nm Pulsed Dye Laser with 1565-nm Nonablative Fractional Laser Safe, Effective for Acnehttps://practicaldermatology.com/news/treatment-of-erythematous-acne-scars-using-595-nm-pulsed-dye-laser-combined-with-1565-nm-resurfx-nonablative-fractional-laser/2462257/The use of a 595-nm pulsed dye laser (PDL) and 1565-nm nonablative fractional laser (NAFL) was seen as safe and efficacious in patients with acne vulgarism, according to a new study in the Journal of Cosmetic Dermatology. "Acne erythema has been considered simple ery
- Fear of Cancer Recurrence Elevated Among Survivors of Localized Cutaneous Melanoma: Analysishttps://practicaldermatology.com/news/lived-experiences-and-fear-of-cancer-recurrence-among-survivors-of-localized-cutaneous-melanoma/2462249/Patients who suffer from localized cutaneous melanoma report high levels of fear of cancer recurrence, according to a new analysis. Researchers investigating the psychological well-being and fear of cancer recurrence among survivors of localized cutaneous melanoma in the United States ev
- Cutera Announces International Commercial Launch of AviClear for the Treatment of Acnehttps://practicaldermatology.com/news/cutera-announces-international-commercial-launch-of-aviclear-for-the-treatment-of-acne/2462240/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- Federated Learning Comparable to Traditional Learning Methods for AI-based Melanoma Diagnosishttps://practicaldermatology.com/news/federated-learning-comparable-to-traditional-learning-methods-for-ai-based-melanoma-diagnosis/2462238/A decentralized federated learning approach was comparable in diagnostic performance to traditional centralized and ensemble learning methods in AI-based melanoma diagnosis, new research suggests. Study authors conducted a multicentric, single-arm diagnostic study conducted across six Ger
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- Interim Analysis: Tralokinumab Improves Quality of Life in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/interim-analysis-tralokinumab-improves-quality-of-life-in-moderate-to-severe-atopic-dermatitis/2462224/Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis sugg